Cowen’s Phil Nadeau joins the bullish conversation buzzing about GWPh’s cannabis-based epilepsy drug after a unanimous nod from the FDA AdCom panel.
Cantor’s Elemer Piros now expects 52% in return potential for GWPH stock and sets a 100% probability of success for Epidiolex.
On back of yesterday’s positive briefing documents, Cowen’s Phil Nadeau roots for FDA approval.
GW Pharmaceuticals (NASDAQ:GWPH) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 11% upturn. …
The hedge fund firm founder is stepping into tech stock HMNY and biopharma stock GWPH; here’s how these Q4 moves measure up against the word on the Street.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is aiming for an EMA marketing green light for Epidiolex, its lead cannabidiol or CBD product candidate, designed …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) investors will be smiling to hear the drug maker’s good news today: FDA acceptance for filing with Priority …
